Study guide
3.2 Ischemic Heart Disease, Acute Coronary Syndromes, & Heart Failure Management
Medical Council of Canada Qualifying Examination Part I MCCQE Part I
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview, Blueprint & Canadian Medical Practice
1.1 MCCQE Part I Format, Scoring (439 Scale), & Strategy 1.2 The MCC Blueprint Matrix: Dimensions of Care & Physician Activities 1.3 Canadian Healthcare System, CanMEDS Roles, & Interprofessional Care 1.4 Evidence-Based Medicine, Study Design, & Clinical Statistics
2 Chapter 2: Population Health, Health Promotion & Preventive Care
2.1 Canadian Task Force on Preventive Health Care (CTFPHC) Screening Guidelines 2.2 Immunization Schedules (NACI) & Vaccine-Preventable Diseases across Lifespan 2.3 Disease Prevention, Lifestyle Counselling, & Harm Reduction 2.4 Outbreak Management, Disease Surveillance, & Infection Control 2.5 Occupational, Environmental, & Travel Medicine in Canada
3 Chapter 3: Internal Medicine — Cardiovascular & Respiratory Systems
3.1 Hypertension Canada 2020/2025 Guidelines, Dyslipidemia, & Primary Prevention 3.2 Ischemic Heart Disease, Acute Coronary Syndromes, & Heart Failure Management 3.3 Arrhythmias, Valvular Heart Disease, & Infective Endocarditis 3.4 Asthma, COPD, & Respiratory Failure (CTS Guidelines) 3.5 Thromboembolic Disease (DVT/PE), Pneumonia, & Pleural Effusions
4 Chapter 4: Internal Medicine — GI, Endocrine, Renal & Hematology/Oncology
4.1 Gastrointestinal Disorders, Acute Abdomen, & Liver/Biliary Disease 4.2 Diabetes Canada 2020/2025 Guidelines & Glycemic Management 4.3 Thyroid, Adrenal, Pituitary, & Electrolyte Disturbances 4.4 Acute Kidney Injury (AKI), Chronic Kidney Disease (CKD), & Nephrology 4.5 Hematology, Anemia Evaluation, Transfusion Medicine, & Common Cancers
5 Chapter 5: General Surgery, Orthopedics, & Emergency Care
5.1 Surgical Evaluation, Preoperative Clearance, & Postoperative Complications 5.2 Trauma Management (ATLS Protocol) & Burns 5.3 Acute Surgical Conditions (Appendicitis, Cholecystitis, Bowel Obstruction) 5.4 Fractures, Dislocations, Joint Pain, & Musculoskeletal Emergencies 5.5 Vascular Emergencies, Wound Care, & Shock Recognition
6 Chapter 6: Pediatrics & Adolescent Health
6.1 Pediatric Growth, Developmental Milestones, & Well-Child Examinations 6.2 Neonatal Resuscitation, Jaundice, & Common Congenital Anomalies 6.3 Pediatric Respiratory Emergencies (Croup, Bronchiolitis, Asthma) 6.4 Common Pediatric Infections, Exanthems, & Fever of Unknown Origin 6.5 Pediatric Abdominal Pain, Dehydration, & Fluid Management
7 Chapter 7: Obstetrics & Gynecology
7.1 Routine Antepartum Care, Screening, & Prenatal Diagnosis (SOGC Guidelines) 7.2 Medical Complications of Pregnancy (Preeclampsia, Gestational Diabetes, Infections) 7.3 Labor, Intrapartum Management, & Postpartum Complications/Hemorrhage 7.4 Abnormal Uterine Bleeding, Gynecologic Infections, & Contraception/Menopause 7.5 Gynecologic Oncology & Pelvic Mass Evaluation
8 Chapter 8: Psychiatry & Mental Health
8.1 Mood Disorders (Depression, Bipolar) & Suicide Risk Assessment 8.2 Anxiety Disorders, OCD, PTSD, & Somatic Symptom Disorders 8.3 Psychotic Disorders & Schizophrenia Management 8.4 Substance Use Disorders, Withdrawal Syndromes, & Harm Reduction 8.5 Pediatric, Perinatal, & Geriatric Psychiatry (Cognitive Impairment / Delirium)
9 Chapter 9: Neurology, Rheumatology, & Dermatology
9.1 Acute Stroke, TIA, & Neurovascular Emergencies 9.2 Headaches, Seizures, Movement Disorders, & Neuromuscular Disease 9.3 Inflammatory Arthritides (RA, Gout, SpA) & Systemic Autoimmune Diseases (SLE, Vasculitis) 9.4 Common Dermatologic Conditions, Cutaneous Manifestations of Systemic Disease, & Skin Cancers 9.5 Musculoskeletal Soft Tissue Injuries, Back Pain, & Physical Medicine
10 Chapter 10: Legal, Ethical, & Professional Behaviours in Canadian Practice
10.1 Informed Consent, Capacity Assessment, & Substitute Decision-Making (CMPA) 10.2 Medical Confidentiality, Privacy Laws (PIPEDA/PHIPA), & Disclosure of Harm 10.3 CMA Code of Ethics, Professionalism, & Physician Health/Boundary Issues 10.4 Mandatory Reporting (Child/Elder Abuse, Driving Safety, Fitness to Practice) & Quality/Safety
3.2 Ischemic Heart Disease, Acute Coronary Syndromes, & Heart Failure Management
Key Takeaways Explain This Topic AI
Immediate 12-lead ECG within 10 minutes of presentation is critical for suspected ACS; ST-elevation MI (STEMI) requires primary PCI within 90 minutes of first medical contact or IV thrombolysis within 30 minutes if PCI transfer exceeds 120 minutes.
Acute Coronary Syndrome medical therapy (MONA-BASH) incorporates dual antiplatelet therapy (ASA plus Ticagrelor or Prasugrel over Clopidogrel) and parenteral anticoagulation.
Stable ischemic heart disease symptom management relies on sublingual nitroglycerin and first-line beta-blockers or calcium channel blockers, alongside secondary prevention with ASA, high-intensity statin, and ACE inhibitors.
Guideline-Directed Medical Therapy (GDMT) for HFrEF (LVEF ≤40%) mandates 'Quad Therapy'—ARNI (sacubitril/valsartan), evidence-based Beta-blocker, Mineralocorticoid Receptor Antagonist (spironolactone/eplerenone), and SGLT2 inhibitor (dapagliflozin/empagliflozin)—to reduce mortality.
Acute decompensated heart failure management relies on hemodynamic profiling ('Warm/Cold' perfusion and 'Dry/Wet' congestion); warm and wet patients require IV loop diuretics and vasodilators if hypertensive, while cold and wet patients require inotropes and diuretic optimization.
Last updated: July 2026
3.2 Ischemic Heart Disease, Acute Coronary Syndromes, & Heart Failure Management
Quick Summary: Acute Coronary Syndrome (ACS) mandates rapid triage with 12-lead ECG within 10 minutes. STEMI requires emergency primary PCI within 90 minutes (or thrombolysis within 30 minutes if PCI transfer time >120 minutes). Dual Antiplatelet Therapy (DAPT) with ASA plus Ticagrelor/Prasugrel is preferred in ACS. Chronic Heart Failure with Reduced Ejection Fraction (HFrEF, LVEF ≤40%) requires mortality-reducing Quad Therapy: ARNI, Beta-blocker, MRA, and SGLT2 inhibitor.
Stable Ischemic Heart Disease (SIHD)
Stable ischemic heart disease presents as predictable chest discomfort provoked by exertion or emotional stress and relieved by rest or sublingual nitroglycerin within 5 minutes.
Diagnostic Evaluation & Risk Stratification
Baseline Workup: Resting 12-lead ECG, fasting lipids, HbA1c, serum creatinine, and transthoracic echocardiogram (TTE) to assess LV function and valvular anatomy.
Non-Invasive Diagnostic Testing:
Exercise Stress Test (Treadmill ECG): Indicated for patients with intermediate pre-test probability, capable of exercise, and having a normal baseline ECG.
Stress Imaging (Stress Echocardiography or Nuclear Myocardial Perfusion Imaging [MPI]): Indicated if baseline ECG is non-diagnostic (e.g., LBBB, ST-segment depression >1 mm, LVH, digitalis effect) or if patient is unable to exercise (pharmacological stress with dobutamine, dipyridamole, adenosine, or regadenoson).
Coronary Computed Tomography Angiography (CCTA): Preferred non-invasive anatomical test in low-to-intermediate probability patients without prior known CAD.
Invasive Coronary Angiography: Gold standard; indicated in high-risk non-invasive test results, persistent refractory angina despite medical therapy, or cardiac arrest survivors.
Pharmacological Management
Symptom Relief: Sublingual Nitroglycerin (0.4 mg SL q5min up to 3 doses for acute angina) + Beta-blockers (first-line anti-anginal; titrate to resting HR 55–60 bpm). Long-acting Calcium Channel Blockers (Dihydropyridine e.g., Amlodipine, or Non-dihydropyridine e.g., Diltiazem if LVEF normal) or Long-acting Nitrates (Isosorbide mononitrate) are added if beta-blockers are insufficient or contraindicated.
Disease-Modifying / Secondary Prevention:
ASA 81 mg daily (or Clopidogrel 75 mg daily if ASA intolerant).
High-Intensity Statin (Atorvastatin 80 mg or Rosuvastatin 40 mg daily).
ACE Inhibitor or ARB (Mandatory if LVEF ≤40%, hypertension, diabetes, or CKD).
Acute Coronary Syndromes (ACS)
ACS encompasses STEMI (ST-elevation MI), NSTEMI (Non-ST-elevation MI), and Unstable Angina (UA) . NSTEMI and UA are collectively termed NSTE-ACS; NSTEMI is distinguished from UA by elevated cardiac biomarkers (high-sensitivity cardiac troponin).
Acute STEMI Management & Reperfusion Benchmarks
STEMI criteria: New ST-segment elevation at the J-point in ≥2 anatomically contiguous leads (≥1 mm in limb leads; ≥1.5–2.5 mm in precordial leads V2–V3 based on sex/age) or new LBBB with ischemic symptoms.
Primary Percutaneous Coronary Intervention (PCI): Preferred reperfusion strategy. Target Door-to-Balloon time ≤90 minutes at a PCI-capable center. If presenting at a non-PCI center, transfer for primary PCI if first medical contact to PCI balloon inflation can be achieved within ≤120 minutes .
Fibrinolytic Therapy: Indicated if primary PCI cannot be delivered within 120 minutes and symptom duration is <12 hours. Target Door-to-Needle time ≤30 minutes using IV Tenecteplase (TNK-tPA). Following fibrinolysis, emergency transfer to a PCI center for rescue PCI (if failed lysis) or routine angiography within 3 to 24 hours is mandatory.
Absolute Contraindications to Thrombolysis: Prior intracranial hemorrhage at any time; known structural cerebrovascular lesion or malignant intracranial neoplasm; ischemic stroke within 3 months; suspected aortic dissection; active internal bleeding (excluding menses); significant closed-head or facial trauma within 3 months.
NSTE-ACS Risk Stratification & Invasive Timing
Urgent Invasive (<2 hours): Hemodynamic instability, cardiogenic shock, refractory chest pain, life-threatening arrhythmias, or acute heart failure.
Early Invasive (<24 hours): Temporal rise/fall in cardiac troponin, dynamic ST/T-wave changes, GRACE risk score >140, or LVEF <40%.
Medical Therapy for ACS (MONA-BASH Paradigm)
Medication Class Agent & Specific Guidance
Morphine IV Morphine reserved only for severe pain refractory to nitrates (caution: may delay P2Y12 absorption).
Oxygen Supplemental O2 indicated only if SpO2 < 90% or patient is in respiratory distress.
Nitrates Sublingual nitroglycerin 0.4 mg q5min x 3, then IV nitroglycerin for ongoing ischemia/hypertension ( Contraindicated in RV infarction or recent PDE-5 inhibitor use ).
ASA Chewable non-enteric coated ASA 160–325 mg immediately, followed by 81 mg daily indefinitely.
P2Y12 Inhibitor (DAPT) Ticagrelor (180 mg loading, 90 mg BID) or Prasugrel (60 mg loading, 10 mg daily) preferred over Clopidogrel (600 mg loading, 75 mg daily) for 12 months.
Anticoagulation Unfractionated Heparin (UFH IV bolus + infusion), Enoxaparin (1 mg/kg SC BID), or Fondaparinux during acute hospitalization.
Beta-Blocker Oral Beta-blocker initiated within 24 hours if no signs of heart failure, low output, or heart block.
ACEi / ARB Initiated within 24 hours, especially if anterior MI, LVEF ≤40%, DM, or HTN.
High-Intensity Statin Atorvastatin 80 mg daily initiated immediately regardless of baseline lipid levels.
Heart Failure Management (CCS 2021/2024 Guidelines)
Heart failure is classified by Left Ventricular Ejection Fraction (LVEF): HFrEF (LVEF ≤40%), HFmrEF (LVEF 41–49%), and HFpEF (LVEF ≥50%).
Guideline-Directed Medical Therapy (GDMT) Quad Therapy for HFrEF
All four foundational drug classes must be initiated and up-titrated promptly to target doses in all HFrEF patients unless contraindicated:
Angiotensin Receptor-Neprilysin Inhibitor (ARNI): Sacubitril / Valsartan
Preferred over ACEi or ARB due to superior reduction in all-cause and CV mortality (PARADIGM-HF trial).
Mandatory Safety Rule: When switching from an ACE inhibitor to Sacubitril/Valsartan, a 36-hour washout period is strictly required to prevent severe, life-threatening angioedema. (No washout required when switching from an ARB).
Evidence-Based Beta-Blocker: Bisoprolol , Carvedilol , or Metoprolol Succinate
Initiate low and titrate slowly once patient is clinically euvolemic. Avoid atenolol or short-acting metoprolol tartrate.
Mineralocorticoid Receptor Antagonist (MRA): Spironolactone (12.5–50 mg daily) or Eplerenone
Reduces mortality and HF hospitalizations. Monitor serum K+ and eGFR; hold if K+ >5.5 mmol/L or eGFR <30 mL/min/1.73m².
SGLT2 Inhibitor: Dapagliflozin (10 mg daily) or Empagliflozin (10 mg daily)
Reduces cardiovascular mortality and HF hospitalizations in HFrEF and HFpEF, regardless of whether the patient has diabetes mellitus .
Loop Diuretics (Furosemide): Administered for symptom relief of congestion and volume overload. Diuretics do not reduce all-cause mortality; doses should be adjusted dynamically based on fluid status.
Advanced Devices in HFrEF
Implantable Cardioverter-Defibrillator (ICD): Primary prevention of sudden cardiac death in patients with ischemic or non-ischemic cardiomyopathy, LVEF ≤35%, NYHA Class II–III symptoms despite ≥3 months of optimal GDMT, and expected survival >1 year.
Cardiac Resynchronization Therapy (CRT-P / CRT-D): Indicated for sinus rhythm, LVEF ≤35%, NYHA Class II–IV despite GDMT, and Left Bundle Branch Block (LBBB) with QRS duration ≥130–150 ms.
Acute Decompensated Heart Failure (ADHF)
ADHF evaluation relies on the Forrester Hemodynamic Matrix based on Perfusion (Warm vs. Cold) and Congestion (Dry vs. Wet):
Warm & Wet (Most Common): Adequate perfusion, elevated filling pressures (orthopnea, JVP elevation, crackles, peripheral edema). Management: IV Loop Diuretics (furosemide IV dose equivalent to 1–2.5x oral daily dose) + IV Vasodilators (Nitroglycerin infusion) if SBP is normal or high.
Cold & Wet (Cardiogenic Shock): Hypoperfusion (cool extremities, oliguria, altered sensorium, narrow pulse pressure) + Congestion. Management: Inotropes ( Dobutamine or Milrinone ) ± Vasopressors ( Norepinephrine if SBP <90 mmHg) + IV loop diuretics once perfusion is restored + emergency mechanical circulatory support (IABP, Impella, ECMO).
Exam Traps & Special Scenarios
Inferior Wall MI & RV Infarction: Inferior MI (ST elevation in II, III, aVF) associated with right ventricular infarction (ST elevation in right-sided V4R lead). Presents with hypotension, clear lungs, and elevated JVP. Nitrates, Morphine, and Diuretics are strictly CONTRAINDICATED due to severe preload dependence; treat hypotension with IV Normal Saline fluid boluses.